Results at 5 Years after Gene Therapy for RPE65-Deficient Retinal Dystrophy

Mark Pennesi, Richard Weleber, Paul Yang, Chris Whitebirch, Beverly Thean, Terence R. Flotte, Margaret Humphries, Elvira Chegarnov, Kathleen N. Beasley, J. Timothy Stout, Jeffrey D. Chulay

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Previously, results at 2 years after subretinal injection of a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65) in eight adults and four children with retinal degeneration caused by RPE65 mutations were reported. Now, results at 5 years after treatment in 11 of these subjects are reported. Subjects received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of two dose levels, and were followed for 5 years after treatment. The primary safety outcomes were ocular and non-ocular adverse events. Efficacy outcomes included changes in best corrected visual acuity, static perimetry hill of vision measurements for the central 30° (V30), and total (VTOT) visual field and kinetic perimetry visual field area. The only adverse events reported during years 3, 4, and 5 were minor intercurrent illnesses. Pediatric subjects had improvement in visual acuity and static perimetry in the treated eye, sometimes with a smaller improvement in the untreated eye, during the first 2 years of the study that persisted during years 3-5, with no consistent changes in kinetic perimetry during the study. Most adult subjects had no consistent changes in visual acuity or static perimetry during the study. Three adult subjects with markedly abnormal baseline kinetic visual field area had improvement in the treated eye during the first 1-2 years after treatment, but the absolute magnitude of the improvement was small and was not sustained at subsequent visits. There were no clinically significant adverse events. Visual acuity and static perimetry testing results suggest that treating patients at a younger age is associated with better visual function outcomes during 5 years after treatment.

Original languageEnglish (US)
Pages (from-to)1428-1437
Number of pages10
JournalHuman Gene Therapy
Volume29
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Retinal Dystrophies
Visual Field Tests
Genetic Therapy
Visual Acuity
Visual Fields
Dependovirus
Retinal Degeneration
Injections
Therapeutics
Pediatrics
Safety
Mutation

Keywords

  • AAV
  • gene therapy
  • Leber congenital amaurosis
  • retinal degeneration
  • RPE65

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Results at 5 Years after Gene Therapy for RPE65-Deficient Retinal Dystrophy. / Pennesi, Mark; Weleber, Richard; Yang, Paul; Whitebirch, Chris; Thean, Beverly; Flotte, Terence R.; Humphries, Margaret; Chegarnov, Elvira; Beasley, Kathleen N.; Stout, J. Timothy; Chulay, Jeffrey D.

In: Human Gene Therapy, Vol. 29, No. 12, 01.12.2018, p. 1428-1437.

Research output: Contribution to journalArticle

Pennesi, M, Weleber, R, Yang, P, Whitebirch, C, Thean, B, Flotte, TR, Humphries, M, Chegarnov, E, Beasley, KN, Stout, JT & Chulay, JD 2018, 'Results at 5 Years after Gene Therapy for RPE65-Deficient Retinal Dystrophy', Human Gene Therapy, vol. 29, no. 12, pp. 1428-1437. https://doi.org/10.1089/hum.2018.014
Pennesi, Mark ; Weleber, Richard ; Yang, Paul ; Whitebirch, Chris ; Thean, Beverly ; Flotte, Terence R. ; Humphries, Margaret ; Chegarnov, Elvira ; Beasley, Kathleen N. ; Stout, J. Timothy ; Chulay, Jeffrey D. / Results at 5 Years after Gene Therapy for RPE65-Deficient Retinal Dystrophy. In: Human Gene Therapy. 2018 ; Vol. 29, No. 12. pp. 1428-1437.
@article{e66650942a274dbabf17ba47f8ca080a,
title = "Results at 5 Years after Gene Therapy for RPE65-Deficient Retinal Dystrophy",
abstract = "Previously, results at 2 years after subretinal injection of a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65) in eight adults and four children with retinal degeneration caused by RPE65 mutations were reported. Now, results at 5 years after treatment in 11 of these subjects are reported. Subjects received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of two dose levels, and were followed for 5 years after treatment. The primary safety outcomes were ocular and non-ocular adverse events. Efficacy outcomes included changes in best corrected visual acuity, static perimetry hill of vision measurements for the central 30° (V30), and total (VTOT) visual field and kinetic perimetry visual field area. The only adverse events reported during years 3, 4, and 5 were minor intercurrent illnesses. Pediatric subjects had improvement in visual acuity and static perimetry in the treated eye, sometimes with a smaller improvement in the untreated eye, during the first 2 years of the study that persisted during years 3-5, with no consistent changes in kinetic perimetry during the study. Most adult subjects had no consistent changes in visual acuity or static perimetry during the study. Three adult subjects with markedly abnormal baseline kinetic visual field area had improvement in the treated eye during the first 1-2 years after treatment, but the absolute magnitude of the improvement was small and was not sustained at subsequent visits. There were no clinically significant adverse events. Visual acuity and static perimetry testing results suggest that treating patients at a younger age is associated with better visual function outcomes during 5 years after treatment.",
keywords = "AAV, gene therapy, Leber congenital amaurosis, retinal degeneration, RPE65",
author = "Mark Pennesi and Richard Weleber and Paul Yang and Chris Whitebirch and Beverly Thean and Flotte, {Terence R.} and Margaret Humphries and Elvira Chegarnov and Beasley, {Kathleen N.} and Stout, {J. Timothy} and Chulay, {Jeffrey D.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1089/hum.2018.014",
language = "English (US)",
volume = "29",
pages = "1428--1437",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Results at 5 Years after Gene Therapy for RPE65-Deficient Retinal Dystrophy

AU - Pennesi, Mark

AU - Weleber, Richard

AU - Yang, Paul

AU - Whitebirch, Chris

AU - Thean, Beverly

AU - Flotte, Terence R.

AU - Humphries, Margaret

AU - Chegarnov, Elvira

AU - Beasley, Kathleen N.

AU - Stout, J. Timothy

AU - Chulay, Jeffrey D.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Previously, results at 2 years after subretinal injection of a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65) in eight adults and four children with retinal degeneration caused by RPE65 mutations were reported. Now, results at 5 years after treatment in 11 of these subjects are reported. Subjects received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of two dose levels, and were followed for 5 years after treatment. The primary safety outcomes were ocular and non-ocular adverse events. Efficacy outcomes included changes in best corrected visual acuity, static perimetry hill of vision measurements for the central 30° (V30), and total (VTOT) visual field and kinetic perimetry visual field area. The only adverse events reported during years 3, 4, and 5 were minor intercurrent illnesses. Pediatric subjects had improvement in visual acuity and static perimetry in the treated eye, sometimes with a smaller improvement in the untreated eye, during the first 2 years of the study that persisted during years 3-5, with no consistent changes in kinetic perimetry during the study. Most adult subjects had no consistent changes in visual acuity or static perimetry during the study. Three adult subjects with markedly abnormal baseline kinetic visual field area had improvement in the treated eye during the first 1-2 years after treatment, but the absolute magnitude of the improvement was small and was not sustained at subsequent visits. There were no clinically significant adverse events. Visual acuity and static perimetry testing results suggest that treating patients at a younger age is associated with better visual function outcomes during 5 years after treatment.

AB - Previously, results at 2 years after subretinal injection of a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65) in eight adults and four children with retinal degeneration caused by RPE65 mutations were reported. Now, results at 5 years after treatment in 11 of these subjects are reported. Subjects received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of two dose levels, and were followed for 5 years after treatment. The primary safety outcomes were ocular and non-ocular adverse events. Efficacy outcomes included changes in best corrected visual acuity, static perimetry hill of vision measurements for the central 30° (V30), and total (VTOT) visual field and kinetic perimetry visual field area. The only adverse events reported during years 3, 4, and 5 were minor intercurrent illnesses. Pediatric subjects had improvement in visual acuity and static perimetry in the treated eye, sometimes with a smaller improvement in the untreated eye, during the first 2 years of the study that persisted during years 3-5, with no consistent changes in kinetic perimetry during the study. Most adult subjects had no consistent changes in visual acuity or static perimetry during the study. Three adult subjects with markedly abnormal baseline kinetic visual field area had improvement in the treated eye during the first 1-2 years after treatment, but the absolute magnitude of the improvement was small and was not sustained at subsequent visits. There were no clinically significant adverse events. Visual acuity and static perimetry testing results suggest that treating patients at a younger age is associated with better visual function outcomes during 5 years after treatment.

KW - AAV

KW - gene therapy

KW - Leber congenital amaurosis

KW - retinal degeneration

KW - RPE65

UR - http://www.scopus.com/inward/record.url?scp=85052071893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052071893&partnerID=8YFLogxK

U2 - 10.1089/hum.2018.014

DO - 10.1089/hum.2018.014

M3 - Article

VL - 29

SP - 1428

EP - 1437

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 12

ER -